Ayala Pharmaceuticals, Inc.
DelistedCIK 1100397fmd_10XGT4Y3WDEH9G7JMETRNGTFF3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2003 to Dec 31, 2023, 64 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (36)
- Net income
- (48)
Latest quarter · Q4 FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (9)
- Net income
- (25)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2023
- -84.1%
- Revenue, 5 yearsFY2019 to FY2023
- -77.2%
- Net income, 5 yearsFY2019 to FY2023
- n/m
Ayala Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $13,000 | 10-K 2024-04-16 · proof | ||
| Gross profit | $0 | $90,000 | -100% | 10-K 2024-04-16 · proof |
| Operating income | -$36.3 million | -$37.5 million | 10-K 2024-04-16 · proof | |
| Net income | -$48.1 million | -$38 million | 10-K 2024-04-16 · proof | |
| Cash from operating activities | -$29.5 million | -$34.5 million | 10-K 2024-04-16 · proof | |
| Total assets | $16.6 million | $7.8 million | +113.4% | 10-K 2024-04-16 · proof |
| Total liabilities | $41 million | $8.9 million | +362.3% | 10-K 2024-04-16 · proof |
| Cash and cash equivalents | $4.9 million | $2.4 million | +102.7% | 10-K 2024-04-16 · proof |
- What was Ayala Pharmaceuticals, Inc.'s revenue in fiscal 2023?
- Ayala Pharmaceuticals, Inc. reported revenue of $13,000 for fiscal 2023 (the year ended Dec 31, 2023). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was Ayala Pharmaceuticals, Inc.'s gross profit in fiscal 2023?
- Ayala Pharmaceuticals, Inc. reported gross profit of $0 for fiscal 2023 (the year ended Dec 31, 2023), against $90,000 the year before (-100%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was Ayala Pharmaceuticals, Inc.'s operating income in fiscal 2023?
- Ayala Pharmaceuticals, Inc. reported operating income of -$36.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$37.5 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was Ayala Pharmaceuticals, Inc.'s net income in fiscal 2023?
- Ayala Pharmaceuticals, Inc. reported net income of -$48.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$38 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was Ayala Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2023?
- Ayala Pharmaceuticals, Inc. reported cash from operating activities of -$29.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$34.5 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What are Ayala Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2023, Ayala Pharmaceuticals, Inc. reported total assets of $16.6 million, against $7.8 million a year earlier (+113.4%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What are Ayala Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2023, Ayala Pharmaceuticals, Inc. reported total liabilities of $41 million, against $8.9 million a year earlier (+362.3%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What are Ayala Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Ayala Pharmaceuticals, Inc. reported cash and cash equivalents of $4.9 million, against $2.4 million a year earlier (+102.7%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1100397&period_type=annual&limit=5"Information only, not investment advice.